Alessandro Lucchesi

Real-world experiences with subcutaneous therapy in adults with primary immune thrombocytopenia: A dual cross-sectional survey study of patients and clinicians in Italy

Esther Natalie Olíva, Alessandra Borchiellini, Giuseppe Carli, Ugo Consoli et autres

Background: Thrombopoietin receptor agonists (TPO-RAs) are frequently prescribed as second-line therapy for immune thrombocytopenia (ITP). Approved TPO-RAs have different characteristics that can influence doctor-patient shared decision-making. Objectives: To gain insight into how ITP and its treatment with subcutaneous TPO-RA are perceived by …

gb, it, us (code pays fourni par la source)

POSTER: MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study

Andrew T Kuykendall, Francesca Palandri, Gregory Sumpao Vosganian, Aniket Bankar et autres

us, it, ca, es, cz, hk, de, au, fr (code pays fourni par la source)

POSTER: MPN-161: Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study

Naveen Pemmaraju, Valentín García‐Gutiérrez, Aniket Bankar, Kristen Marie Pettit et autres

us, es, ca, it, cz, hk, au, de, fr (code pays fourni par la source)

POSTER: MPN-298: Correlation Among IL-8, TNF-α, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor in the IMbark Trial

John O Mascarenhas, Claire N. Harrison, Alessandro Lucchesi, Angela Fleischman et autres

us, gb, it, fr (code pays fourni par la source)

MPN-674: Preliminary Data From Ongoing Global Phase 1/2 Study of Investigational PIM1 Inhibitor Nuvisertib in Combination With Momelotinib Show Promising Clinical Activity in Patients With Myelofibrosis and Anemia

Andrew Srisuwananukorn, James McCloskey, Lindsay Rein, John O Mascarenhas et autres

us, ca, jp, be, it, au, fr, gb, de (code pays fourni par la source)

POSTER: MPN-674: Preliminary Data From Ongoing Global Phase 1/2 Study of Investigational PIM1 Inhibitor Nuvisertib in Combination With Momelotinib Show Promising Clinical Activity in Patients With Myelofibrosis and Anemia

Andrew Srisuwananukorn, James McCloskey, Lindsay Rein, John O Mascarenhas et autres

us, ca, jp, be, it, au, fr, gb, de (code pays fourni par la source)

MPN-985: Effect of Rusfertide on Cytoreductive Therapy Use in Patients With Phlebotomy-Dependent Polycythemia Vera: Post Hoc Analysis From the Randomized Controlled Phase 3 VERIFY Study

Andrew T Kuykendall, Francesca Palandri, Gregory Sumpao Vosganian, Aniket Bankar et autres

us, it, ca, es, cz, hk, au, de, fr (code pays fourni par la source)

POSTER: MPN-318: Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials

Pankit Vachhani, Alessandro Lucchesi, Andrew Charles Perkins, Jasmine Sahni et autres

us, it, au (code pays fourni par la source)

MPN-298: Correlation Among IL-8, TNF-α, and Overall Survival in Imetelstat-Treated Patients With Myelofibrosis Relapsed or Refractory to a Janus Kinase Inhibitor in the IMbark Trial

John O Mascarenhas, Claire N. Harrison, Alessandro Lucchesi, Angela Fleischman et autres

us, gb, it, fr (code pays fourni par la source)

MPN-318: Characterization of Symptoms After Immediate Transition From Ruxolitinib to Momelotinib in Patients With Myelofibrosis: Post-Hoc Analyses of the Phase 3 SIMPLIFY-1 and SIMPLIFY-2 Trials

Pankit Vachhani, Alessandro Lucchesi, Andrew Charles Perkins, Jasmine Sahni et autres

us, it, au (code pays fourni par la source)

MPN-161: Benefit of Rusfertide Maintained in Patients With Low-Risk or High-Risk Polycythemia Vera: Efficacy and Safety Subgroup Analysis From the Randomized Controlled Phase 3 VERIFY Study

Naveen Pemmaraju, Valentín García‐Gutiérrez, Aniket Bankar, Kristen Marie Pettit et autres

us, es, ca, it, cz, hk, au, de, fr (code pays fourni par la source)

Efficacy of pacritinib versus momelotinib in patients with thrombocytopenic myelofibrosis: a matching-adjusted indirect treatment comparison

Naveen Pemmaraju, Alessandro Lucchesi, Stephen T. Oh, Koo Wilson et autres

Thrombocytopenia is a prognostic marker in patients with myelofibrosis, associated with increased morbidity and reduced survival. We conducted a matching-adjusted-indirect-comparison (MAIC) of pacritinib-vs-momelotinib for treatment of patients with thrombocytopenic myelofibrosis. Data were from Phase 3 randomized controlled trials of patients with thrombocytopenic …